Exact Sciences Corporation (NASDAQ:EXAS) – Analysts at Craig Hallum raised their Q3 2017 EPS estimates for Exact Sciences Corporation in a note issued to investors on Thursday. Craig Hallum analyst B. Bonello now anticipates that the medical research company will post earnings of ($0.35) per share for the quarter, up from their previous estimate of ($0.38). Craig Hallum also issued estimates for Exact Sciences Corporation’s Q4 2017 earnings at ($0.36) EPS, FY2017 earnings at ($1.41) EPS, Q1 2018 earnings at ($0.33) EPS, Q2 2018 earnings at ($0.33) EPS and FY2018 earnings at ($1.28) EPS.

A number of other equities analysts have also recently issued reports on EXAS. Cowen and Company started coverage on Exact Sciences Corporation in a report on Monday, March 27th. They set an “outperform” rating and a $30.00 target price on the stock. Bank of America Corporation restated a “buy” rating on shares of Exact Sciences Corporation in a report on Wednesday, March 29th. Leerink Swann started coverage on Exact Sciences Corporation in a report on Monday, April 17th. They set an “outperform” rating and a $30.00 target price on the stock. Canaccord Genuity restated a “buy” rating and set a $27.00 target price on shares of Exact Sciences Corporation in a report on Monday, April 24th. Finally, Zacks Investment Research cut Exact Sciences Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Exact Sciences Corporation presently has an average rating of “Buy” and an average target price of $33.85.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/10/exact-sciences-corporation-expected-to-earn-q3-2017-earnings-of-0-35-per-share-exas.html.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) opened at 37.03 on Monday. The firm’s 50-day moving average price is $33.86 and its 200 day moving average price is $24.14. Exact Sciences Corporation has a 12-month low of $11.94 and a 12-month high of $38.92. The firm’s market cap is $4.12 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Thursday, April 27th. The medical research company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.09. The company had revenue of $48.36 million during the quarter, compared to the consensus estimate of $37.38 million. Exact Sciences Corporation had a negative net margin of 116.39% and a negative return on equity of 49.24%. Exact Sciences Corporation’s revenue was up 225.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.49) EPS.

A number of large investors have recently made changes to their positions in the stock. Neuberger Berman Group LLC purchased a new stake in shares of Exact Sciences Corporation during the first quarter worth about $6,391,000. Nationwide Fund Advisors raised its stake in shares of Exact Sciences Corporation by 52.1% in the first quarter. Nationwide Fund Advisors now owns 149,167 shares of the medical research company’s stock worth $3,523,000 after buying an additional 51,085 shares in the last quarter. State Street Corp raised its stake in shares of Exact Sciences Corporation by 11.7% in the fourth quarter. State Street Corp now owns 5,554,992 shares of the medical research company’s stock worth $74,211,000 after buying an additional 582,802 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Exact Sciences Corporation during the fourth quarter worth about $758,000. Finally, Norges Bank purchased a new stake in shares of Exact Sciences Corporation during the fourth quarter worth about $25,200,000. 84.96% of the stock is currently owned by institutional investors and hedge funds.

In other news, SVP D Scott Coward sold 1,987 shares of Exact Sciences Corporation stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the transaction, the senior vice president now owns 57,603 shares in the company, valued at approximately $2,028,201.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.00% of the company’s stock.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History and Estimates for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.